前列腺癌、前列腺增生症患者血清骨保护素测定的临床价值

摘要

目的 探讨前列腺癌(PCa)患者和前列腺增生(BPH)症患者血清中骨保护素(OPG)浓度的差异以及前列腺癌患者骨保护素浓度与血清前列腺特异性抗原(PSA)水平、前列腺体积是否具有相关性.方法 采用双抗体夹心酶免法(ELISA)测定40例前列腺癌患者及40例前列腺增生患者血清OPG浓度,同时采集PCa患者的前列腺体积及PSA值.比较PCa患者及BPH患者血清OPG浓度的差异以及前列腺癌患者中OPG浓度与PSA、前列腺体积之间有无相关性.结果 PCa患者的血清OPG浓度平均值水平[(14 900.19士5 168.65)pg/mL]显著高于BPH组[(10 457.87土4 786.29) pg/mL],差异有显著性意义(P＜0.01).PCa患者血清OPG浓度与PSA值及前列腺体积之间均无明显相关性(r分别为=0.221、0.138,P均＞0.1).结论 血清OPG浓度对鉴别PCa和BPH有重要临床价值,PCa患者血清OPG浓度与血清PSA值及前列腺体积无明显相关性.%Objective To evaluate the significance of serum osteoprotegerin(OPG) in assessing prostate cancer(Pca) and benign prostatic hyperplasia(BPH), and to determine the correlation between concentration of OPG and serum PSA value and prostate volume. Methods The concentration of OPG was measured with ELISA in 40 patients with prostatic carcinoma and 40 patients with BPH. The relationship between OPG concentrations and PSA or prostate volume was calculated in patients with Pca. Results The OPG concentration was (14 900.19±5 168.65)pg/mL in the prostatic carcinoma group, which was significantly higher than that in the BPH group (10 457.87±4 786.29)pg/mLCP＜0.05). The level of OPG was not correlated with PSA (r = 0. 221, F= 0.171) or prostate volume (r = 0.138, P =0.396). Conclusion Serum OPG level is clinically significant in differentiating Pca and BPH, but it has no significant correlation with serum PSA value or prostate volume.